Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Rutherford

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Blood Advances|December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific WorkshopReid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Hemasphere|November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposureMwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The New England Journal of Medicine|October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's LymphomaAlex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826Sharon M Castellino, Hongli Li, Alex F Herrera, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Blood Advances|December 3, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific WorkshopReid W Merryman, Sarah C Rutherford, Stephen M Ansell, et al.
Hemasphere|November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposureMwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The New England Journal of Medicine|October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's LymphomaAlex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.
Pageof 4